“I have severe asthma and I’m living my life”

prescribed biologic indicated for severe eosinophilic asthma*—
27,000 patients and counting"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1
* Source: IQVIA - NPATM audit: 12 mo. TRX data ending 7/18 (All rights reserved).
December 2015 to August 2018 data sourced from IQVIA and GSK. Claims data based on total number of unique patients who had at least one claim for NUCALA in the United States. Not all patients remained on therapy. Individual results may vary.

NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

Actual patient compensated by GSK for her time.
“I HAVE SEVERE ASTHMA AND I’M LIVING MY LIFE”
Actual patient compensated by GSK for her time.
#1 prescribed biologic indicated for severe eosinophilic asthma*—
27,000 patients and counting"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1
* Source: IQVIA - NPATM audit: 12 mo. TRX data ending 7/18 (All rights reserved).
December 2015 to August 2018 data sourced from IQVIA and GSK. Claims data based on total number of unique patients who had at least one claim for NUCALA in the United States. Not all patients remained on therapy. Individual results may vary.

Choose NUCALA for:

Powerful Protection
From Exacerbations2‡

Powerful Reduction
in OCS Dose

Lasting Evidence1‖

MENSA (Trial 2): 32-week study comparing NUCALA 100 mg to placebo, each added to SOC in 576 patients with severe eosinophilic asthma. Primary Endpoint Results: Frequency of exacerbations. NUCALA: 0.83/year, placebo: 1.74/year; P<0.001. Secondary Endpoint Results: Frequency of exacerbations requiring hospitalization and/or ED visit; NUCALA: 0.08/year; placebo: 0.20/year; P=0.02.

§SIRIUS (Trial 3): 24-week study comparing NUCALA 100 mg to placebo in 135 patients with severe eosinophilic asthma receiving prednisone 5-35 mg (or equivalent) per day and regular use of high-dose ICS and 1 other controller. Primary Endpoint Results: Percent reduction in daily OCS dose (Weeks 20 to 24) while maintaining asthma control vs placebo; P=0.008.

COLUMBA: 4.5-year open-label study assessing the safety, immunogenicity, and efficacy of NUCALA 100 mg added to asthma controller therapy in 347 patients with severe eosinophilic asthma.

STUDY DESIGNS AND PRIMARY ENDPOINT RESULTS

See how NUCALA reduces eosinophil levels

Chat